Drug
Tev 53275 Dose A
Tev 53275 Dose A: highest development phase Phase 2, developed by Teva. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Teva
Trials
| Drug | Phase | Indication |
|---|---|---|
| TEV-53275 Dose A NCT04847674 | Phase 2 | Asthma |
Latest
No recent events.
Follow Tev 53275 Dose A on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.